This nonrandomized controlled trial evaluates anti–epidermal growth factor receptor (EGFR) rechallenge therapy in patients in Italy with circulating tumor DNA (ctDNA) RAS/BRAF wild-type (wt) metastatic colorectal cancer. Here, EGFR is linked to neoplasm.